Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Cholinesterase inhibitory activity of extracts, fractions (in 500 µg/mL), and compounds 1–5 (in 40 µg/mL) a of S. aristata

From: Neuroprotective, and memory enhancement effects of Salvia aristata and its phenolic constituents: an in vitro, and in vivo study

Sample

AChE inhibition %

BChE inhibition %

SADE

3.66 ± 0.69

35.86 ± 1.77

SAHE

62.74 ± 3.57 (IC50 = 339.8 µg/mL, 95% CI: 294.9-384.8)b

15.21 ± 1.15

Fraction I

23.42 ± 0.09

5.72 ± 1.60

Fraction II

21.66 ± 0.19

0.81 ± 0.12

Fraction III

19.48 ± 0.11

1.12 ± 0.31

Fraction IV

27.77 ± 0.31

17.93 ± 2.10

Fraction V

6.49 ± 0.06

0.90 ± 0.21

Compound 1

10.91 ± 1.30

18.41 ± 2.72

Compound 2

11.93 ± 2.51

5.86 ± 0.91

Compound 3

6.55 ± 0.22

10.97 ± 0.18

Compound 4

11.54 ± 0.19

10.97 ± 0.77

Compound 5

10.03 ± 0.08

3.08 ± 0.18

Donepezil

89.11 ± 3.73 (IC50 = 0.02 µM, 95% CI: 0.01–0.03)

86.60 ± 4.81 (IC50 = 1.92 µM, 95% CI: 1.82–2.03)

  1. a Inhibition percent are presented as mean ± SD (three independent experiments)
  2. b The IC50 value was calculated for the sample exhibiting inhibitory activity exceeding 50%
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us